Quinine

Introduction Overview

Generic Name

quinine

Brand Name

Qualaquin, QM-260, Quinamm

Dosage Form

oral capsule (324 mg)

Drug Class

Antimalarial quinolines

Pharmacokinetics

Absorption:
Quinine is well absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations are typically reached within 1 to 3 hours. However, absorption can be affected by concurrent ingestion of antacids containing magnesium or aluminum, which may reduce the bioavailability of quinine by binding the drug in the GI tract and impairing its absorption. Taking quinine with food can improve gastrointestinal tolerability but may slightly delay absorption. Extensive first-pass metabolism in the liver reduces its bioavailability, with oral bioavailability approximately 70-85%. Clinical implications include the necessity to avoid co-administration with certain antacids to maintain effective plasma levels.

Distribution:
Quinine is widely distributed throughout body tissues and fluids, including the plasma, liver, kidneys, and muscle, with a volume of distribution averaging between 2 to 4 L/kg in adults. It crosses the placenta and can be found in breast milk, posing potential risks to the fetus and nursing infants. Approximately 70-90% of quinine binds to plasma proteins, mainly albumin, which influences its free active concentration. The drug's distribution to various tissues plays a crucial role in its antimalarial activity, especially in erythrocytes where Plasmodium parasites reside.

Metabolism:
Quinine undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, especially CYP3A4. It is demethylated and hydroxylated to form multiple metabolites, some of which retain pharmacological activity. Metabolic rate may vary significantly due to genetic polymorphisms, liver function status, and interactions with other drugs that induce or inhibit CYP3A4. These interactions necessitate careful clinical monitoring and possible dosage adjustments to avoid toxicity or subtherapeutic effects.

Elimination:
Quinine and its metabolites are excreted primarily via the kidneys, with 20-30% of unchanged quinine eliminated in urine. The elimination half-life ranges from approximately 10 to 12 hours, but this can be prolonged in cases of renal insufficiency or liver impairment. Renal clearance may be altered by urinary pH and other drugs, affecting quinine plasma levels. Slow elimination increases the risk of accumulation and toxicity, particularly important in patients with compromised renal or hepatic function. Monitoring quinine plasma levels can be useful in some clinical settings to optimize therapy and minimize adverse effects.

Dosage Forms

Available Dosage Forms:
Quinine is formulated as oral capsules, available specifically as 324 mg quinine sulfate per capsule. This is the standard dosing form approved for use in treating uncomplicated malaria.

Dosages for Adults and Adolescents:
The typical oral dosage for treatment of uncomplicated malaria in adults and adolescents aged 16 years and older is 324 mg every 8 hours (three times daily) for 7 days. Dosage adjustments may be necessary based on patient response, weight, and clinical condition. It is recommended to take the capsules with food to reduce gastrointestinal side effects.

Specific Patient Populations:
Use in pediatric patients under 16 years old is not recommended due to safety concerns and lack of sufficient data. In patients with renal or hepatic impairment, quinine clearance may be reduced, necessitating careful clinical monitoring and possible dosage adjustments. Pregnancy category C indicates potential risk; quinine should be used during pregnancy only if clearly needed. Breastfeeding mothers should consult healthcare providers since quinine is excreted in breast milk and may affect the infant.

Mechanism Of Action

Quinine exerts its antimalarial effect primarily through interference with the parasite's ability to metabolize and detoxify heme during the intraerythrocytic stage of Plasmodium species. When Plasmodium parasites digest hemoglobin within red blood cells, free heme is released, which is toxic to the parasite. Quinine binds to this heme, preventing its polymerization into the non-toxic hemozoin, thereby accumulating toxic levels of heme and leading to parasite death.

At the molecular level, quinine inhibits the heme detoxification pathway by binding both free heme and hemozoin. This leads to oxidative stress and disruption of parasite membrane integrity. Cellularly, quinine affects the parasite's food vacuole, a specialized organelle where hemoglobin digestion occurs, impairing its function and leading to the accumulation of toxic intermediates.

Biochemically, quinine acts as a weak base and can interfere with ion transport and membrane potential in the parasite. It also modulates calcium channels affecting parasite motility and replication. These multiple biochemical interactions culminate in the inhibition of Plasmodium growth and replication.

Clinically, quinine offers effective treatment for uncomplicated malaria, particularly for Plasmodium falciparum strains that are resistant to other antimalarials. Compared to related drugs such as quinidine, quinine is favored due to a better safety profile and oral bioavailability. Research studies have confirmed quinine’s efficacy in clearing parasitemia and reducing morbidity when used as monotherapy or in combination with other antimalarial agents. However, resistance development and adverse effect profiles necessitate cautious clinical use.

Pharmacological Actions

Antimalarial activity through inhibition of Plasmodium heme detoxification.
Interference with parasite food vacuole function disrupting hemoglobin digestion.
Induction of oxidative stress in Plasmodium species leading to parasite death.
Weak base properties altering parasite intracellular pH and ion transport.
Modulation of calcium ion channels affecting parasite replication and motility.
Rapid reduction of parasitemia in uncomplicated malaria infections.
Anti-inflammatory effects secondary to parasite clearance.
Pharmacodynamic properties favor oral administration with adequate bioavailability.
Potential off-label muscle relaxant effects though not FDA-approved.
Effects on cardiac conduction at higher doses, requiring careful monitoring.

Therapeutic Or Clinical Uses

Treatment of uncomplicated Plasmodium falciparum malaria infections.
Alternative therapy in regions with chloroquine-resistant malaria strains.
Adjunctive treatment in combination antimalarial regimens.
Symptomatic treatment of malaria-associated symptoms such as fever and chills.
Historical off-label use for nocturnal leg cramps (not FDA-approved).
Not indicated for prophylaxis or prevention of malaria.
Use restricted per FDA regulations to approved brands only.
Considered in malaria infections when other antimalarials are contraindicated.
Investigational uses in certain parasitic infections beyond malaria.
Avoidance of use in severe or complicated malaria cases requiring parenteral therapy.

Side Or Adverse Effects

Headache and dizziness, including lightheadedness and vertigo.
Visual disturbances such as blurred vision and changes in color perception.
Tinnitus (ringing in the ears) which may be an early sign of quinine toxicity.
Gastrointestinal upset including nausea, vomiting, abdominal pain, and diarrhea.
Sweating, flushing, and facial warmth as common transient effects.
Serious allergic reactions such as urticaria, angioedema, and anaphylaxis.
Severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Blood disorders including thrombocytopenia, hemolytic anemia, and leukopenia.
Cardiac side effects such as arrhythmias, including prolonged QT interval and tachycardia.
Hypoglycemia, particularly in pregnant women, manifesting as sweating, hunger, and confusion.
Tinnitus and hearing loss (cinchonism) at higher or prolonged doses.
Renal impairment and acute kidney injury, manifested by dark urine and decreased urine output.
Respiratory symptoms including wheezing, cough, and in rare cases pulmonary edema.
Neurological symptoms such as visual or auditory hallucinations, confusion, and vertigo.
Rare reports of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals.

Precautions

Avoid use in patients with known allergy to quinine or related compounds like quinidine and mefloquine.
Use cautiously in patients with cardiac conduction abnormalities, especially Long QT syndrome.
Careful monitoring in patients with liver or renal impairment to prevent accumulation.
Not recommended in pediatric patients under 16 years due to limited safety data.
Avoid during pregnancy unless benefits outweigh risks; category C drug.
Monitor blood glucose closely in diabetic or pregnant patients due to hypoglycemia risk.
Discontinue immediately if signs of severe hypersensitivity or blood disorders develop.
Use with caution in patients with myasthenia gravis or optic neuritis.
Warn patients about potential vision and hearing disturbances affecting alertness.
Avoid concomitant use with drugs that prolong QT interval to reduce arrhythmia risk.
Educate patients on the importance of adherence to the full course of therapy for malaria.
Advise patients to report symptoms such as unusual bleeding, severe headache, or chest pain.
Avoid self-medication for leg cramps due to serious potential adverse effects.
Advise against alcohol consumption which may exacerbate side effects.
Use cautiously when combined with medications that interact via CYP3A4 metabolism.

Warnings

Quinine can cause serious and life-threatening cardiac, hematologic, renal, and neurological adverse effects.
Risk of severe hypersensitivity reactions including anaphylaxis requiring immediate medical attention.
Contraindicated in patients with Long QT syndrome due to risk of fatal arrhythmias.
Potential for serious bleeding and thrombocytopenia requiring immediate cessation.
High risk of hypoglycemia, particularly in pregnant women, which can lead to seizures or coma.
Use may cause hemolysis in individuals with G6PD deficiency, hence screening is advised before administration.
Not approved for prevention of malaria or use in severe malaria cases.
Risk of optic neuritis and irreversible blindness with repeated or prolonged use.
Do not use in patients with history of quinine-induced blood cell disorders or severe hemorrhage.
Avoid use in patients with myasthenia gravis due to potential exacerbation of muscle weakness.
May cause thrombocytopenic purpura and hemolytic uremic syndrome with high morbidity.
Use only approved quinine formulations; FDA has banned all non-approved quinine products.
Patients must be warned about the risk of serious skin reactions such as Stevens-Johnson syndrome.
Potential interactions may increase quinine toxicity; careful drug history is essential.
Patients should be cautioned against the use of quinine for leg cramps due to fatal risks.

Contraindication

Known hypersensitivity or allergy to quinine or chemically related compounds (quinidine, mefloquine).
History of quinine-induced thrombocytopenia, hemolytic anemia, or other blood dyscrasias.
Diagnosed Long QT syndrome or other significant cardiac conduction disorders.
Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) due to risk of hemolysis.
Myasthenia gravis due to risk of exacerbating muscle weakness.
Active optic neuritis or inflammatory optic nerve disorders.
Previous severe bleeding attributed to quinine therapy.
Severe hepatic or renal impairment without close monitoring and dosage adjustment.
Use in children under 16 years of age due to safety concerns.
Use in prevention of malaria or treatment of severe/complicated malaria (requires other therapies).
Concomitant use with drugs that strongly prolong QT interval without medical supervision.

Drug Interactions

Antacids containing magnesium or aluminum can reduce quinine absorption and efficacy.
CYP3A4 inhibitors like ketoconazole, itraconazole, and voriconazole may increase quinine plasma levels causing toxicity.
CYP3A4 inducers such as carbamazepine, phenobarbital, and rifampin may reduce quinine efficacy by increasing metabolism.
Other QT-prolonging drugs (amiodarone, sotalol, quinidine, macrolide antibiotics) may increase arrhythmia risk.
Co-administration with anticoagulants may potentiate bleeding risk.
Co-administration with antiretroviral drugs (ritonavir, saquinavir) may alter quinine levels through CYP interactions.
Cimetidine and ranitidine may increase quinine concentrations due to CYP450 inhibition.
Drugs that affect heart rate or rhythm (digoxin, beta-blockers, calcium channel blockers) require monitoring.
Use with antidepressants (amitriptyline, venlafaxine, nefazodone) may increase toxicity risk.
Macrolide antibiotics such as erythromycin and clarithromycin can increase quinine levels.
St John's Wort induces CYP3A4, lowering quinine blood levels and reducing effectiveness.
Drugs causing hypokalemia or hypomagnesemia may exacerbate quinine-induced arrhythmias.
Concomitant use of dolasetron, ondansetron, or droperidol heightens QT prolongation potential.
Tacrolimus and methadone interacting may affect quinine clearance and cardiac safety.
Multiple antimalarial combinations should be avoided unless under strict medical supervision.

Preparations Of The Drug

Quinine sulfate oral capsules containing 324 mg of quinine base.
FDA-approved brand: Qualaquin indicated for treatment of uncomplicated malaria.
Formulated for oral administration with instructions to take with food.
Available in prescription-only formulations due to safety monitoring requirements.
Not available as intravenous or parenteral formulations for malaria treatment (other agents preferred).
No FDA-approved formulations for prophylactic or leg cramp indications.
Manufactured under strict regulatory standards to ensure purity and potency.
Packaging includes full prescribing information and warnings regarding serious adverse effects.
No known approved generic oral tablets; availability often through selected branded products.
Storage conditions require room temperature away from moisture and heat to maintain stability.
Not formulated for topical or over-the-counter use; all usage must be under physician supervision.
Patients provided with clear guidance on missed doses and overdose emergency procedures.
Specialized packaging for safe handling advised due to potential toxicities upon accidental ingestion.
Prescribing information emphasizes use in adults and adolescents aged 16 years and over.
All formulations accompanied by patient information leaflets detailing risks and precautions.